Retatrutide: What the Research Actually Shows

What It Is

A Triple Receptor Agonist, Not Just Another GLP-1

Retatrutide is a synthetic peptide and triple receptor agonist, it activates the GIP, GLP-1, and glucagon receptors simultaneously. It's Eli Lilly's investigational compound (LY3437943), currently in Phase 3 trials, not an approved drug. Mechanistically, it's a direct extension of the same GIP/GLP-1 signaling family as semaglutide and tirzepatide already on this site, retatrutide adds glucagon receptor agonism on top, which is thought to add direct energy-expenditure and hepatic fat-metabolism effects beyond the appetite and insulin-sensitivity effects GLP-1/GIP agonism already provides.

The Evidence

Mechanism, Diabetes Trial, and Obesity Trial, Graded Separately

Mechanism

Li W, Zhou Q, Cong Z, et al. "Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide." Cell Discovery. 2024 Jul 17;10:77. doi: 10.1038/s41421-024-00700-0. Cryo-EM structures of retatrutide bound to all three receptors, resolved to 2.68-3.26 Å. The paper shows how the molecule maintains contact with conserved residues shared across the three receptors while also accommodating receptor-specific differences, particularly a loop region (ECL1) that's rigid in two of the three receptors but flexible in the third, structural biology, not a clinical outcome, but a solid, independently-reviewed mechanistic basis for how one molecule can activate three different receptors at once.

Structural Biology (Cryo-EM) · Endpoint: Mechanism Only

Type 2 Diabetes, Published RCT

Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet. 2026;407:2402-13. doi: 10.1016/S0140-6736(26)00967-0. PMID: 42250575. ClinicalTrials.gov: NCT06354660. 537 adults with type 2 diabetes (baseline A1c 7.0-9.5%), 40-week randomized, double-blind, placebo-controlled design. A1c fell 1.69% (4 mg), 1.86% (9 mg), and 1.94% (12 mg) from baseline, a 1.12 percentage-point difference versus placebo at the highest dose (95% CI -1.39 to -0.85, P<.0001). Body weight fell 11.5% (4 mg) to 15.3% (12 mg), roughly 15.1 kg at the highest dose. This is real, published, peer-reviewed randomized trial data, the strongest evidence tier on this page.

Phase 3 RCT, Peer-Reviewed & Published · Endpoint: A1c & Body Weight, T2D Population

Obesity, Conference-Presented, Not Yet Peer-Reviewed

Jastreboff AM. "Results of first phase 3 study of retatrutide, a GIP, GLP-1, and glucagon receptor agonist in patients with obesity (TRIUMPH-1)." Symposium presentation, ADA 2026 Scientific Sessions, June 6, 2026. 2,339 adults with obesity or overweight, 80-week trial. As presented: average weight loss of 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) at the highest dose. We're reporting these figures because they're from a large, apparently well-designed phase 3 trial presented at a legitimate scientific meeting, but as of this writing we could not find a peer-reviewed journal publication for TRIUMPH-1 the way TRANSCEND-T2D-1 has one. Conference-presented data hasn't been through peer review, the full methods and complete results aren't available for independent scrutiny yet, and conference-stage efficacy numbers have occasionally shifted once the full paper publishes. Treat the obesity figures above as preliminary until that happens, we'll update this page once TRIUMPH-1 is formally published.

Phase 3 Trial, Conference-Presented, Not Yet Peer-Reviewed · Endpoint: Body Weight, Obesity Population, Preliminary

Sources

References